Clinical Pharmacokinetics of Pravastatin
- 1 August 1994
- journal article
- review article
- Published by Springer Nature in Clinical Pharmacokinetics
- Vol. 27 (2), 94-103
- https://doi.org/10.2165/00003088-199427020-00002
Abstract
The hypolipidaemic agent pravastatin differs from other US Food and Drug Administration (FDA)-approved HMG-CoA reductase inhibitors (e.g. lovastatin and simvastatin) because it has greater...Keywords
This publication has 43 references indexed in Scilit:
- Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II)1993
- Comparative efficacy and safety of pravastatin and cholestyramine alone and combined in patients with hypercholesterolemia. Pravastatin Multicenter Study Group II.1993
- Effect of food on pravastatin pharmacokinetics and pharmacodynamics.1993
- A quarter century of drug treatment of dyslipoproteinemia, with a focus on the new HMG-CoA reductase inhibitor fluvastatin.1993
- Clinical Pharmacokinetics and Practical Applications of SimvastatinClinical Pharmacokinetics, 1993
- Comparative Pharmacokinetics of Lovastatin, Simvastatin and Pravastatin in HumansThe Journal of Clinical Pharmacology, 1992
- Concentrations of Pravastatin and Lovastatin in Cerebrospinal Fluid in Healthy SubjectsClinical Neuropharmacology, 1991
- Pharmacokinetics and pharmacodynamics of pravastatin alone and with cholestyramine in hypercholesterolemiaClinical Pharmacology & Therapeutics, 1990
- Determination of pravastatin sodium and its major metabolites in human serum/plasma by capillary gas chromatography/negative ion chemical ionization mass spectrometryJournal of Mass Spectrometry, 1989
- ML-236A, ML-236B, and ML-236C, new inhibitors of cholesterogensis produced by Penicillium citrinum.The Journal of Antibiotics, 1976